Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuvation Bio Inc.NUVB · Entity 4384 | SEE REMARKS | February 27, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuvation Bio Inc.
Report date February 27, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 68,137 |
Reported balance
After 2026-02-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-27 · Grant · Acquired 50,761 · Balance 68,137 F1: Represents the grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock upon settlement. 25% of the shares subject to the RSUs shall vest on the Issuer's quarterly vesting date following each of the first four anniversaries from 2/27/2026, subject to Reporting Person's continuous service on each such vesting date. F2: Includes 1,001 shares acquired on May 19, 2025 and 1,100 shares acquired November 19, 2025 under the 2021 Employee Stock Purchase Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.91 · Expires 2036-02-26 | Direct | 224,439 |
Reported balance
After 2026-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-27 · Grant · Acquired 224,439 · Balance 224,439 F3: Option vests as to 25% on the one year anniversary of 2/27/26, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock upon settlement. 25% of the shares subject to the RSUs shall vest on the Issuer's quarterly vesting date following each of the first four anniversaries from 2/27/2026, subject to Reporting Person's continuous service on each such vesting date.
F2: Includes 1,001 shares acquired on May 19, 2025 and 1,100 shares acquired November 19, 2025 under the 2021 Employee Stock Purchase Plan.
F3: Option vests as to 25% on the one year anniversary of 2/27/26, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2026 Filed Mar 4, 2026 01:03 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 224,439 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0002001938-26-000004 · form4-03042026_010328.xml · derivative · entry 2 Makunje Moses · CIK 0002001938 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,439 Underlying: Class A Common Stock · 224,439 shares Expires 2036-02-26 F3 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/27/26, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:03 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantClass A Common Stock | 50,761 | $0.00 | $0.00 |
DisclosureSEC source: 0002001938-26-000004 · form4-03042026_010328.xml · nonDerivative · entry 1 Makunje Moses · CIK 0002001938 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,137 F1 · shares: Represents the grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock upon settlement. 25% of the shares subject to the RSUs shall vest on the Issuer's quarterly vesting date following each of the first four anniversaries from 2/27/2026, subject to Reporting Person's continuous service on each such vesting date. F2 · balance_after: Includes 1,001 shares acquired on May 19, 2025 and 1,100 shares acquired November 19, 2025 under the 2021 Employee Stock Purchase Plan. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 23:34 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001415889-25-006697 · form4-03042025_110346.xml · derivative · entry 2 Makunje Moses · CIK 0002001938 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Class A Common Stock · 250,000 shares Expires 2035-02-27 F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2025, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 22:22 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantClass A Common Stock · Derivative | 250,000 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001415889-24-006308 · form4-03042024_100351.xml · derivative · entry 1 Makunje Moses · CIK 0002001938 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Class A Common Stock · 250,000 shares Expires 2034-02-27 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.